THE PHILIPPINE STOCK EXCHANGE

PSEi
  • Snapshot
  • About
  • Country
  • List Of Stars
Last Price
00
GMT / 25 SEP 2017
Value Change [%]
0.00
[ 0.00 %]
Open
00
Day's High
00
Year's High
8,322
Previous Close
8,245
Day's Low
00
Year's Low
6,084
  •    CEO
  •    O/L
PhStockExchange
@PhStockExchange
25
Sep
Volume turnover 1.59bn shares valued at Php6.76bn; foreign buying Php2.82bn and foreign selling Php2.81bn.
25
Sep
September 25, 2017: PSEi closed at 8,244.73 down 36.54 points or 0.44 percent. #PSEiupdate https://t.co/aVQlXm5gps
25
Sep
As of 3:05 p.m., PSEi 8,199.25 down 82.02 points or 0.99 percent. #PSEiupdate
25
Sep
As of 2:15 p.m., PSEi 8,204.59 down 76.68 points or 0.93 percent. #PSEiupdate
25
Sep
As of 1:35 p.m., PSEi 8,211.30 down 69.97 points or 0.84 percent. #PSEiupdate
25
Sep
As of 12:00 noon, market recess, PSEi 8,216.47 down 64.80 points or 0.78 percent. #PSEiupdate https://t.co/GKnm3QFRz7
25
Sep
As of 11:30 a.m., PSEi 8,208.61 down 72.66 points or 0.88 percent. #PSEiupdate
25
Sep
As of 11:00 a.m., PSEi 8,216.14 down 65.13 points or 0.79 percent. #PSEiupdate
25
Sep
As of 10:30 a.m., PSEi 8,219.59 down 61.68 points or 0.74 percent. #PSEiupdate
25
Sep
Asia United Bank declares 50 centavos cash dividend per common share https://t.co/5aaDpQ3h0r
25
Sep
As of 10:05 a.m., PSEi 8,228.40 down 52.87 points or 0.64 percent. #PSEiupdate
25
Sep
September 25, 2017: As of 9:35 a.m., PSEi 8,244.17 down 37.10 points or 0.45 percent. PSEi opened at 8,247.41. #PSEiupdate
22
Sep
Volume turnover 3.07bn shares valued at Php6.15bn; foreign buying Php2.82bn and foreign selling Php2.50bn.
22
Sep
September 22, 2017: PSEi closed at 8,281.27 down 5.59 points or 0.07 percent. #PSEiupdate https://t.co/Yl5HePYnvF
22
Sep
As of 3:15 p.m., PSEi 8,275.45 down 11.41 points or 0.14 percent. #PSEiupdate
22
Sep
As of 2:35 p.m., PSEi 8,284.68 down 2.18 points or 0.03 percent. #PSEiupdate
22
Sep
As of 2:05 p.m., PSEi 8,291.25 up 4.39 points or 0.05 percent. #PSEiupdate
22
Sep
As of 1:35 p.m., PSEi 8,281.94 down 4.92 points or 0.06 percent. #PSEiupdate
22
Sep
As of 12:00 noon, market recess, PSEi 8,278.56 down 8.30 points or 0.10 percent. #PSEiupdate https://t.co/UagnNf3tU2
22
Sep
As of 11:30 a.m., PSEi 8,293.66 up 6.80 points or 0.08 percent. #PSEiupdate
  • FTSE Analytics
  • Market News
25 September 2017 - reuters.com
20 September 2017 - reuters.com
14 September 2017 - reuters.com
14 September 2017 - reuters.com
6 September 2017 - reuters.com
Patient assistance charity says U.S. contacted it in probe
25 September 2017
source: reuters.com

By Nate Raymond BOSTON, Sept 25 (Reuters) - A U.S. charity that offers assistance to patients seeking help to cover out-of-pocket drug costs on Monday said it has been contacted in a connection with federal investigation into drugmakers' financial support of non-profits like itself. Patient Services Inc's disclosure came after the U.S. Justice Department on Friday said one of its donors, Aegerion Pharmaceuticals Inc, illegally used the non-profit to defray co-payments for patients prescribed an expensive cholesterol drug. The Justice Department made that claim in papers filed in Boston federal court as part of Aegerion's agreement to plead guilty to two misdemeanors and pay $40.1 million to resolve probes into its marketing of the drug, Juxtapid. urn:newsml:reuters.com:*:nL2N1M31DN Aegerion, a Novelion Therapeutics Inc NVLN.O unit, is one of around a dozen drugmakers that have disclosed investigations into their support of charities that help patients cover co-payments. Patient Services Inc (PSI) in a statement said it cooperated in the Aegerion investigation. It also said it has been contacted as part of the overall charity-related inquiry by the U.S. Attorney's Office in Massachusetts and is cooperating. "PSI operates under guidelines set by the U.S. Health and Human Services Department Office of the Inspector General and does not 'funnel funds' for manufacturers," PSI said. Drug companies are prohibited from subsidizing co-payments for patients enrolled in government healthcare programs like Medicare. But companies may donate to non-profits providing co-pay assistance as long as they are independent. Amid increased attention to rising drug prices, concern has arisen that donations from drugmakers to patient-assistance groups may be contributing to price inflation. Companies including Pfizer Inc and Johnson & Johnson have received subpoenas seeking information related to their support of such charities. United Therapeutics Corp UTHR.O in July said it set aside $210 million to resolve claims arising from the probe. In Aegerion's case, prosecutors said after the U.S. Food and Drug Administration in 2012 approved Juxtapid for treating high cholesterol in people with a rare genetic disease, Aegerion promoted it for patients who did not have the condition. The U.S. Attorney's Office also as part of a civil settlement said Aegerion violated a anti-kickback law by funneling funds through PSI to induce Juxtapid purchases by defraying patient's co-payment obligations for the drug, which eventually cost $330,000 annually. The government alleged PSI promoted its ability to create a "reimbursement vehicle" for Aegerion, which was able to eliminate price sensitivity for Juxtapid via a fund PSI created that Aegerion funded. (Reporting by Nate Raymond in Boston; Editing by Marguerita Choy) ((Nate.Raymond@thomsonreuters.com and Twitter @nateraymond; 617-856-1312; Reuters Messaging: nate.raymond.thomsonreuters.com@reuters.net)) Keywords: NOVELION THERAPE SETTLEMENT/CHARITY

Sign up for our newsletter
Submit
Interested to know more?